Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer

Matthew Wagner, Mark Garzotto, Dianne Lemmon, Kristine M. Eilers, Tomasz M. Beer

    Research output: Contribution to journalArticlepeer-review

    3 Scopus citations

    Abstract

    A 66-year-old man with androgen-independent prostate cancer was treated with abarelix, a gonadotropin-releasing hormone antagonist, for 20 weeks in an experimental protocol. He did not respond to therapy, but his serum prostate-specific antigen level dropped from 15.8 ng/mL to a confirmed 0.8 ng/mL after abarelix was stopped. His prostate-specific antigen level did not return to greater than 15.8 ng/mL for 14 months. This is the first report of a withdrawal response after therapy with a gonadotropin-releasing hormone antagonist, a new class of agents for prostate cancer. Additional observations are needed to determine whether this is an isolated case or a harbinger of a more common phenomenon.

    Original languageEnglish (US)
    Pages (from-to)799.e37-799.e39
    JournalUrology
    Volume65
    Issue number4
    DOIs
    StatePublished - Apr 2005

    ASJC Scopus subject areas

    • Urology

    Fingerprint Dive into the research topics of 'Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer'. Together they form a unique fingerprint.

    Cite this